Resverlogix Corp. (“Resverlogix”) (TSX: RVX) is pleased to announce that it has expanded its Cardiovascular Disease (CVD) research efforts focused on vascular inflammation (VI). “Preliminary findings demonstrated that NexVas™ compounds have inhibitory effects on a number of inflammation markers comparable to and better than our positive control, a chemical entity representative of Atherogenics Inc’s vascular inflammatory drug (AGI-1067) currently in pivotal phase 3 clinical studies (ARISE),” stated Donald J. McCaffrey, President and CEO of Resverlogix. “Currently, our compounds are early in development and have not yet surpassed the AGI-1067 control in potency. However, having successfully increased the potency of our NexVas PR compounds, we are confident in our ability to improve potency with ongoing chemistry efforts and mining of our patent estate,” McCaffrey added.
